Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11010
Title: A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Authors: Gan, Hui K;Rosenthal, Mark A;Dowling, Anthony;Kalnins, Renate M;Algar, Elizabeth;Wong, Nicholas;Benson, Angela;Woods, Anne-Marie;Cher, Lawrence M
Affiliation: Departments of Medical Oncology, Austin Health, Melbourne, Victoria, Australia. hui.gan@ludwig.edu.au
Issue Date: 8-Feb-2010
Citation: Neuro-oncology 2010; 12(5): 500-7
Abstract: Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles). The primary endpoint was 6-month progression-free survival (PFS) with response rate (RR), median PFS, and median overall survival (OS) as secondary endpoints. Of 39 evaluable patients at the 6-month time point (median follow-up, 34 months), 6-month PFS was 77% (95% confidence interval [CI], 74.5%-79.3%). There were 15 complete responses (CRs, 38%), 6 partial responses (PRs, 15%), and 9 disease stabilization (23%). The median PFS was 21 months (95% CI, 3-39 months), and the median OS was 43 months (95% CI, 20-66 months). Chromosome 1p/19q codeletions were seen in 47% (18 of 38) of the patients, and O-6-methylguanine-DNA-methyltransferase (MGMT) methylation was seen in 48% (10 of 21) of the patients. All patients with OD showed MGMT methylation and most (71%) had chromosome 1p/19q codeletions. Conversely, fewer patients with OA showed MGMT methylation (23%) or had chromosome 1p/19q codeletions (31%). The presence of either 1p/19q codeletion or MGMT methylation was associated with increased RR at 6 months but not with improved PFS or OS. Only 18% of the patients (7 of 40) experienced treatment-related grade 3/4 toxicities. This regimen was active and well tolerated. These data add to the growing body of data showing that primary chemotherapy may be an acceptable alternative to radiotherapy for patients with gliomas containing oligodendroglial histology.
Internal ID Number: 20406900
URI: http://ahro.austin.org.au/austinjspui/handle/1/11010
DOI: 10.1093/neuonc/nop065
URL: http://www.ncbi.nlm.nih.gov/pubmed/20406900
Type: Journal Article
Subjects: Adolescent
Adult
Aged
Antineoplastic Agents.therapeutic use
Brain Neoplasms.drug therapy.genetics.pathology
Chromosomes, Human, Pair 1.genetics
Chromosomes, Human, Pair 19.genetics
DNA Methylation
DNA Modification Methylases.genetics
DNA Repair Enzymes.genetics
Dacarbazine.analogs & derivatives.therapeutic use
Disease-Free Survival
Female
Gene Deletion
Humans
Kaplan-Meier Estimate
Loss of Heterozygosity
Male
Middle Aged
Oligodendroglioma.drug therapy.genetics.pathology
Tumor Suppressor Proteins.genetics
Young Adult
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.